Table 1.
Characteristic | Total | TRK−, % of total=column 2 | TRK+, % of total=column 2 | P, between TRK+ and TRK− |
---|---|---|---|---|
Patients, no. (%) | 94 | 42 (45) | 52 (55) | |
Age, y | ||||
Mean | 54.3 | 52.9 | 55.5 | .41 |
Range | 16-79 | 20-77 | 16-79 | |
Sex, no. | .17 | |||
Male | 52 | 27 | 25 | |
Female | 42 | 15 | 27 | |
Leukemia, no. (%) | .358 | |||
AML | 82 | 39 (48) | 43 (52) | |
ALL | 11 | 3 (27) | 8 (73) | |
AUL | 1 | 0 | 1 | |
Diagnosis (AML), no. (%) | .057 | |||
De novo | 58 | 32 (55) | 26 (45) | |
Post-MDS/secondary | 24 | 7 (29) | 17 (71) | |
FAB subtype AML | .003 | |||
M0 | 3 | 3 | 0 | |
M1 | 25 | 16 | 9 | |
M2 | 17 | 10 | 7 | |
M3 | 1 | 1 | 0 | |
M4 | 21 | 9 | 12 | |
M5 | 13 | 0 | 13 | |
M6 | 1 | 0 | 1 | |
M7 | 1 | 0 | 1 | |
% Blasts | ||||
Bone marrow | 73 | 76 | 70 | .280 |
Peripheral blood | 44 | 49 | 39 | .173 |
WBC counts, ×109/L | ||||
Mean | 24.4 | 61.0 | .113 (cutoff: 20.000)40 | |
Range | 0.8-159.0 | 0.6-454.0 | ||
ECOG status | .764 | |||
0 | 22 | 10 | 12 | |
1 | 52 | 25 | 27 | |
2 | 13 | 7 | 6 | |
3 | 1 | 0 | 1 | |
Cytogenetics, no. (%) | .481 | |||
Normal karyotype | 39 | 17 (44) | 22 (56) | |
t(8;21) (q22;q22) | 1 | 1 | 0 | |
inv(16) (p13q12) | 1 | 1 | 0 | |
t(15:17)(q22;q11-21) | 1 | 1 | 0 | |
t(11q23) | 2 | 1 | 1 | |
Complex karyotype* | 21 | 11 | 10 | |
Other aberrations | 24 | 8 | 16 | |
FLT3-ITD−, no. (%) | 50 | 26 (52) | 24 (48) | .363 |
FLT3-ITD+, no. (%) | 17 | 6 (35) | 11 (65) | |
Missing | 17 (18) |
Complex karyotype was defined as 3 or more cytogenetic abnormalities in the absence of t(8;21), inv(16), t(15;17), or t(11q23).41